Karen Marie Walker - Apr 11, 2025 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Chief Technology Officer
Signature
By: /s/ Ryan Jones, as Attorney-in-Fact
Stock symbol
KYTX
Transactions as of
Apr 11, 2025
Transactions value $
$0
Form type
4
Date filed
4/15/2025, 05:40 PM
Previous filing
Jun 10, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Award $0 +13K +134.91% $0.00 22.6K Apr 11, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Stock Option (right to buy) Award $0 +80K $0.00 80K Apr 11, 2024 Common Stock 80K $2.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2 1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.